$RLFTF (related) copy by frenchman yhoobrd - Many of us

New Post Public Reply Private Reply Replies (0) Message Board
mc67
647
$RLFTF (related) copy by frenchman yhoobrd - Many of us here have been lambasting the FDA for their delay tactics- word is starting to spread:

“FDA regulators are wasting precious time in greenlighting a COVID vaccine as more than 2,000 Americans are dying each day and the pandemic continues to starve American society.

Pfizer submitted data detailing the safety and effectiveness of its vaccine on Nov. 22. But rather than immediately convening experts, the FDA scheduled a review meeting on Dec. 10, almost three weeks later. As Pfizer’s application sits on the shelf at the FDA awaiting authorization, about 27,000 Americans will have died. So what is the FDA doing for three weeks?

As a Johns Hopkins scientist who has conducted more than 100 clinical studies and reviewed thousands more from the scientific community at large, I can assure you that the agency’s review can be done within 24 to 48 hours without cutting any corners. They just need to work harder.

Contrary to popular belief, the FDA process is not hands-on—it does not interview vaccine trial patients or look under a microscope at the immune cells. It’s doing a statistical analysis and looking at data. For the vaccine trial, the data set is small and straightforward. If my research team, normally tasked with analyzing data on millions of patients, was asked to review the smaller Pfizer vaccine study of 43,000 patients, it would take about one hour.

The FDA also reviews manufacturing data from Pfizer on how they made the drug. But not only can that data be reviewed in a few hours, it should have been done months ago when it was available. While the FDA was waiting for Pfizer’s long-term vaccine results to come in, the agency should have anticipated this step and done it early.

The final step of the FDA review is to look at the outcomes of the study volunteers, including rates and severity of infection and side effects in the vaccine and placebo groups. Again, there is no plausible reason why this basic analysis cannot be done in 24 hours. The FDA and external scientists have a simple task: confirm or reject the review already conducted by the trial’s independent data safety monitoring board before FDA submission.

Let me be clear: The agency should not cut any corners in its review process, just cut out the sitting-around time. FDA insiders say the agency and its approximately 17,000 employees were dark for the four-day Thanksgiving holiday, including those working on the vaccine approval. It’s time the FDA adopts a sense of urgency. We’ve had Operation Warp Speed in developing vaccines but Operation Turtle Speed in reviewing the results...”

https://thedispatch.com/p/fda-career-staff-are-delaying-the

- some replies -

Zaran
thank you, sorry state we are in


m
@Bridge for future reference I would just have someone focus on the most efficacious of the two which is RLF-100, right? I don’t known if leronlimab is putting out numbers that are overall better than Aviptadil.


Bridge
I tweeted to Dr. Makary, responding to an earlier tweet of his. I know it’s probably useless, and after all what could he do? But I find myself sending out a tweet every few days to someone who may be able to raise these concerns. Maybe better than just watching this nightmarish delay, which makes so little sense.

Read your article re FDA vaccine delay. Same with COVID TREATMENTS like #Leronlimab and #Aviptadil
- In trials since April/May
- MOA against COVID is known
- Qualify for EUA: are SAFE and without doubt “may be” effective
- FDA is taking so long while so many die
- Can you help?


m
Dr. Marty should have focused on RLF-100 and it’s slow progress because it has a known safety profile whereas vaccines are not as well known. Pushing out RLF-100 in the 10’s of millions this December would have done more than the vaccines will. I could be wrong but would love to learn why.


Bridge
Thanks for posting. What an indictment! And that’s just the vaccines. We all knew it didn’t make sense that viable treatments like RLF-100 and leronlimab are still sitting on the shelf.

What the hell is going on? I don’t think it can be corruption like big pharma money. No half-way normal person would allow tens of thousands of deaths for money. It must be some combination of things like human complacency and stupidity. It’s hard to witness this nightmare.


crymeariver
They should focus on saving dying people instead of vaccinating healthy people.


frenchman
@BigGator There doesn’t seem to be a sense of urgency - the question is why?
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Helio Fred Garcia Honored by Diversity Action Alliance

Updated Category News Views 4

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 4

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
XKL Delivers MediaLight for High-Speed Optical Transport

Updated Category News Views 0

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

Continue Reading
AI Trust in Finance: Survey Reveals Market Impact

Updated Category News Views 2

Trust in AI for Financial Guidance: Where Are We Headed? The market winds shift with every sunrise, and today’s buzzword? Artificial Intelligence. You’d almost think AI’s trying to steal my job along with every other trader’s mojo. But here's the twist—A survey from Possible Finance shows about 15% of folks would actually lean on AI for their financial advice....

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 1

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
Red-Eye Flights Surge, Driven By Western U.S. Routes

Updated Category News Views 4

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Continue Reading
Rare Collectibles Highlight Morphy's Auction on Oct 4

Updated Category News Views 2

Anticipation Builds for Morphy's Auction Event Morphy's upcoming event on October 4th is all about tapping into the era of revved engines, gleaming gasoline signs, and some history that could put Hollywood tales to shame. The auction isn't just a stroll down memory lane; it features over 650 lots, each a time capsule of America's automotive past. From Al Capone's ritzy...

Continue Reading
Havoc, CSBC Partner for Autonomous Maritime Future

Updated Category News Views 3

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Continue Reading
Diaper Affordability: A Hidden Crisis, Taxpayer Burden

Updated Category News Views 6

A Silent Crisis Lurking in Diapers Diapers. We don’t think about them much until we need them, but nearly half of U.S. families are painfully aware of their cost. According to a report from the NDBN Diaper Check 2026, many struggle to meet this basic necessity. This isn't just about keeping babies clean—it's a public health issue with economic ripples Congress can't...

Continue Reading
Cannabis Industry Pushes for Robust Financial Services

Updated Category News Views 4

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

Continue Reading

Top 5 Most Recently Viewed Articles

A Look Back: $100 Invested in Westinghouse Air Brake Today

Updated Category News Views 91

Understanding the Growth of Westinghouse Air Brake Westinghouse Air Brake has shown remarkable performance over the last two decades, outpacing the market significantly. With an annualized return of 14.89%, this company has established itself as a strong contender in its sector, and its current market capitalization stands impressively at $33.98 billion. Investment...

Continue Reading
Exploring the Growing Impact of Procurement Software Solutions

Updated Category News Views 230

Understanding the Procurement Software Landscape The procurement software market is rapidly evolving, with its value poised at $7.96 billion in 2024 and an anticipated growth to $17.87 billion by 2033. This growth translates to a compound annual growth rate (CAGR) of 9.4% from 2025 to 2033. Procurement software plays a crucial role in how organizations efficiently procure...

Continue Reading
Streamside RV Resorts: Embracing Slow Summer Travel

Updated Category News Views 9

Reimagining the Summer Getaway There's a fresh breeze blowing through the travel industry, and Streamside RV Resorts is right in the mix of it, pushing the envelope with their latest venture. They're teaming up with Outdoorsy, Charbroil, and Ranger Station to reimagine the summer getaway. It's a one-of-a-kind call to action against the relentless hustle and bustle modern...

Continue Reading
Employers Holdings, Inc. Achieves Top Insurance Ratings Upgrade

Updated Category News Views 127

Employers Holdings, Inc. Receives AM Best Upgrade Employers Holdings, Inc. (NYSE:EIG), a well-known name in workers’ compensation insurance, has exciting news to share: AM Best has upgraded the Financial Strength Rating (FSR) of its insurance subsidiaries from A- to A, which denotes an Excellent rating. Notably, the Long-Term Issuer Credit Ratings (Long-Term ICR) for...

Continue Reading
The Hartford Financial Services Group Receives Positive Credit Ratings

Updated Category News Views 373

AM Best granted The Hartford Financial Services Group, Inc. solid Long-Term Issue Credit Ratings back in 2024. They rolled out an impressive ‘a-’ rating for senior unsecured issues, alongside a ‘bbb+’ for senior subordinated issues, and a ‘bbb’ rating for junior subordinated and preferred stock tied to their new shelf registration. This was a big deal; traders...

Continue Reading